Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Santen Pharmaceutical Co., Ltd.

https://www.santen.com/en/

Latest From Santen Pharmaceutical Co., Ltd.

End Of US FDA’s Very Fast Reviews? 2022 Novel Approvals Stayed Close To PDUFA Timeframes

Moderation was a theme of the year in novel approvals, as CDER’s median review time rose for the first time in five years and even the center’s fastest approval took more than seven months. A Pink Sheet infographic breaks down which review pathways did the best last year. 

Pink Sheet Perspectives US FDA Performance Tracker

Trials In Focus: How COVID-19 Studies Set New Standards For Collaboration, Diversity

JAMA reports on the COVID-19 Prevention Network’s efforts. Also, Inhibikase said the US FDA lifted a hold on its drug for Parkinson’s disease, while Astellas Pharma said the agency lifted a clinical hold on its gene therapy for Pompe disease. And Trefoil, Theriva Biologics and Nektar initiated new trials.

Clinical Trials Coronavirus COVID-19

Chinese Biotechs Raise $212m Through Major VC/PE Deals in November

Leading the group were Trinomab Biotech, which develops antibodies for infectious diseases, and cell and gene developers BRL Medicine and XellSmart.

China Financing

Researcher At Heart: Toichi Takenaka's Journey From 'Empty Lab' To CEO

Dr Toichi Takenaka, the first winner of the Lifetime Achievement Award in the inaugural Pharma Intelligence Awards Japan earlier this year, talks to Scrip about his journey from researcher to CEO and today as a mentor for Japanese bioventures. Starting his career in an “empty lab” in the 1960s motivated him to pursue a string of collaborations with universities in Japan and on to the discovery of four successful drugs.

Japan Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Eyevance Pharmaceuticals LLC.
    • Novagali Pharma SA
    • Santen Inc.
    • Chongqing Santen Kerui Pharmaceutical Co., Ltd
    • InnFocus Inc,
UsernamePublicRestriction

Register